Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.44 |
| ▸ | HTR1E | P28566 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359443 | 1.00 | HTR1D (0.44) | HTR1DHTR1EHTR1ANAMPTMEN1 | |
| SCHEMBL21382793 | 0.85 | NAMPT (0.41) | NAMPTRAB9A | |
| SCHEMBL19359218 | 0.83 | NAMPT (0.46) | NAMPTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL19380845 | 0.81 | NAMPT (0.41) | HTR1DHTR1EHTR1ANAMPTKMT2A | |
| SCHEMBL3710183 | 0.78 | EPHX1 (0.45) | NAMPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19359153 | 0.77 | PARP10 (0.42) | HTR1DHTR1EHTR1AKMT2A | |
| SCHEMBL14755669 | 0.70 | PARP10 (0.44) | — | |
| SCHEMBL28413199 | 0.70 | POLB (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28413023 | 0.70 | POLB (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13734425 | 0.70 | POLB (0.45) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |